Multiple Sclerosis Drugs Market to Exhibit 6.7% CAGR, Leading Companies Focus on Strategic Collaborations to Expand Their Footprint

Multiple Sclerosis Drugs Market Summarized details by key players are Biogen, Pfizer, Inc., Hoffmann-La Roche Ltd, Merck & Co., Inc., Novartis AG, Sanofi, Teva Pharmaceutical Industries Ltd. and Other players


Pune, India -- (SBWIRE) -- 06/18/2019 -- The Global Multiple Sclerosis Drugs Market is expected to gain from the development of economical therapy to treat multiple sclerosis (MS), finds Fortune Business Insights in a report, titled "MULTIPLE SCLEROSIS DRUGS: GLOBAL MARKET ANALYSIS, INSIGHTS, AND FORECAST, 2019-2026." According to the report, the global market was worth US$ 23,460.3 Mn in 2018. The market is anticipated to expand at a CAGR of 6.7% and reach US$ 39,289.5 Mn by the end of 2026. The report offers a comprehensive overview of the global multiple sclerosis drugs market.

Sample PDF Brochure at

Some of the major companies that are present in the Global Multiple Sclerosis Drugs Market are;

- Biogen
- Pfizer, Inc.
- Hoffmann-La Roche Ltd
- Merck & Co., Inc.
- Novartis AG
- Sanofi
- Teva Pharmaceutical Industries Ltd.
- Other players

As per the report, North America emerged dominant in the global market in 2018. The regional market was valued at US$ 13,826.7 Mn in 2018. The North America market is anticipated to expand and continue to dominate the market during the forecast period 2019-2026. It is driven by the increasing demand for and the high price of multiple sclerosis drugs. Additionally, several key market players operating in this region. Several among them are awaiting approval from the authorities for their newly developed therapeutics. This is expected to increase the growth rate in the global market. Europe is anticipated to stand second on the leading list by the end of 2026. The growth witnessed is attributable to increasing government spending and recommendations for multiple sclerosis treatment. This is expected to fuel the demand in the region. Besides this, Asia Pacific is anticipated to expand at the highest CAGR during the forecast period. Healthcare sector emerging in nations such as China and India is expected to contribute towards the Asia Pacific market expansion.

In 2018, Biogen collaborated with Eisai Co. Ltd. to promote Tecfidera, Tysabri, and Avonex in Japan. This is anticipated to increase the demand in the global market.

Development of New Therapeutics to Propel Growth

In terms of the route of administration, the injection segment was leading the market in 2018 and is anticipated to expand considerably over the forecast period. The growth witnessed is attributable to the active government recommendation for the injection.

Development of new therapeutics for treating multiple sclerosis and rising awareness about the disease are expected to drive the global multiple sclerosis drugs market. Additionally, increasing per-capita income and increasing healthcare expenditure are some factors anticipated to fuel the demand in the global market.

On the flip side, high cost associated with multiple sclerosis drugs and treatment and lack of availability of drugs are factors that may hamper the growth in the global market.

Major Table of Content Multiple Sclerosis Drugs Market is;

4. Key Insights
4.1 Prevalence of Multiple Sclerosis - For Key Countries, 2018
4.2 Regulatory Scenario - For Key Countries
4.3 Patent Snapshot
4.4 New Drug Class Launch
4.5 Pipeline Analysis
4.6 Key Industry Developments - Mergers, Acquisitions, and Partnerships

Tecfidera's Increasing Sale to Drive Biogen's Growth in the Global Market

Biogen emerged as the leading player in the global multiple sclerosis market in 2018, owing to the high sales of Tecfidera. Biogen is expected to witness impressive growth during the forecast period gaining from strategical partnering with other players to widen the distribution network. Besides this, Novartis AG is also among the leading organizations. Owing to the high demand for Gilenya, Novartis holds a strong position in the global market. In 2018, the National Institute for Health and Care Excellence announced to recommend Extavia among other beta interferon drugs such as Avonex, Betaferon and Rebif. This is anticipated to contribute towards Novartis's market position. Further, this is anticipated to fuel the demand for multiple sclerosis treatment and drugs. Some of the companies operating in the global market are Pfizer, Inc., F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Sanofi, and Teva Pharmaceutical Industries Ltd.

Browse Complete Report Details at

About us:

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.